“…The introduction of continuous processing has been a paradigm shift in safety and productivity in the synthesis and isolation of active pharmaceutical ingredients (APIs) in both industry and academic research (Mascia et al, 2013 andLee et al, 2015 and references contained therein). A major focus of our current research is developing design and optimization strategies to deliver robust, scalable and tunable continuous processes for API manufacturing, which can deliver specific API characteristics (Power et al, 2015;Zhao et al, 2015;O'Mahony et al, 2017;Simon et al, 2018). As part of this work we have been examining the continuous crystallization of 2-chloro-N-(p-tolyl)propanamide, 1, a key intermediate of -thio--chloroacrylamides, a class of compound that has shown importance in the literature as synthetically viable APIs (Murphy et al, 2007;Foley et al, 2011;) that can undergo transformations; such as Diels-Alder cycloadditions (Kissane et al, 2010a), 1,3-dipolar cycloadditions (Kissane et al, 2010b), sulfide group (Kissane et al, 2010c,d) and nucleophilic substitution .…”